ESSA Pharma Announces Initiation of A Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination With Enzalutamide Among Patients With Metastatic Castration-Resistant Prostate Cancer

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

ESSA Pharma Announces Initiation of A Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination With Enzalutamide Among Patients With Metastatic Castration-Resistant Prostate Cancer

header-info

Sep, 18, 2023

Based on results to be presented at the 2023 ESMO Congress, researchers have initiated a phase 2 study to evaluate masofaniten plus anti-androgen enzalutamide among patients with metastatic castration-resistant prostate cancer, naive to second generation antiandrogens.

Access the full article to read more here.